The vaping industry faces new hurdles with the FDA’s recent regulations, puzzling many with the intricate requirements of the Pre-Market Tobacco Applications (PMTA). The sudden inclusion of vaping devices, which are tobacco-free, under these regulations has caught many off-guard. The decision by the Office of Information and Regulatory Affairs (OIRA) and the Office of Management and Budget (OMB) to support FDA’s stance marks the countdown to a comprehensive federal scrutiny of the industry, set to commence within three months.
From mango vape juice to tobacco nicotine salts, countless vape shop proprietors accustomed to concocting their unique e-liquid flavors, the specifics of these ‘deeming regulations’ remain somewhat nebulous.
The new mandate insists on every e-liquid undergoing the PMTA, but the FDA has been ambiguous about the precise financial implications. Their approximation suggests a 500-hour, $300,000 procedure for one application. However, industry insiders speculate a steeper climb — potentially 1500 to 1700 hours and over $1 million for each product. This scenario gets more complex considering each nicotine level and flavor combination necessitates a separate application.
Assuming a 500-hour process, that translates to nearly 21 days. Is it feasible for the FDA to evaluate millions of applications within such a tight frame? This conundrum presents a looming question.
- Product prices are poised to increase.
- Product diversity is threatened.
- The era of vape mods could be over.
The financial burden of the astronomical PMTA costs will inevitably fall on the consumer, leading to pricier e-liquids and a significant reduction in flavor options. Moreover, the era of customized vape mods might be drawing to a close. These devices, known for their personalization, consist of several components that could each face stringent approval processes, making them financially unfeasible for manufacturers.
These changes are still theoretical, and the industry is clamoring for clarity. The Cole-Bishop Amendment, which proposes adjusting the foundational predicate date from February 15, 2007, to a more recent one, might offer some reprieve. However, it is a stopgap measure. The real challenge lies in convincing a Republican-majority Congress to counteract the FDA’s stringent stance.